TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21610513
Drug: benidipine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipine and thiazide diuretic
Study: 17972364
Drug: 5 STIs
Normalized name: Stissera Curcuma Root
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 STIs of 1, 1, 2, 2, and 3 months' duration, each followed by 3 months of therapy
Study: 17972364
Drug: Unboosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unboosted protease inhibitor (PI)-based HAART
Study: 17972364
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitor-based HAART
Study: 15143085
Drug: Low-dose HER‐2/neu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose HER‐2/neu ICD protein vaccine (25 microg)
Study: 15143085
Drug: Intermediate-dose HER‐2/neu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose HER‐2/neu ICD protein vaccine (150 microg)
Study: 15143085
Drug: High-dose HER‐2/neu
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HER‐2/neu ICD protein vaccine (900 microg)
Study: 15143085
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of HER‐2/neu ICD protein vaccine
Study: 11801946
Drug: TCRF turbinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCRF turbinate treatment (mean energy 415 +/- 37 J/turbinate; n = 17)
Study: 9494309
Drug: Perceived control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived control over pain and taking pain medication
Study: 2461906
Drug: 10% hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydroxyethyl starch (HES) solution
Study: 2461906
Drug: 10% dextran
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextran solution
Study: 30033775
Drug: CARE Healthy
Normalized name: CHLOROXYLENOL 0.005 mg in 1 mL TOPICAL LIQUID [PURELL Healthcare HEALTHY SP 0.5pct PCMX Antimicrobial Foam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARE Healthy Lifestyles intervention (includes educational workshop, informational magazine, goal setting, weekly self-monitoring, tailored feedback, prompts, team-based goals, coaching for directors)
Study: 29625849
Drug: AbobotulinumtoxinA (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA (both doses)
Study: 16688464
Drug: Concurrent pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent pain in axial, upper limb, and lower limb areas
Study: 11012500
Drug: Isobaric 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric 2% lidocaine 4 ml intrathecally
Study: 11012500
Drug: Isobaric 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isobaric 2% prilocaine 4 ml intrathecally
Study: 26832658
Drug: IAI 2
Normalized name: Intravitreal aflibercept injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAI 2 mg every 8 weeks after 5 monthly doses (2q8)
Study: 15539894
Drug: Calcipotriol/betamethasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol/betamethasone dipropionate followed by calcipotriol 50 microg/g once daily
Study: 15539894
Drug: Tacalcitol 4
Normalized name: Tacalcitol 4 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacalcitol 4 microg/g once daily
Study: 11157302
Drug: Glucagon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (1 mg IV)
Study: 11157302
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mg IV)
Study: 11157302
Drug: Open-label glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open-label glucagon (1 mg IV)
Study: 9691869
Drug: DCLHb 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb 400 mg kg‐1 i.v.
Study: 26709158
Drug: Tobramycin powder
Normalized name: tobramycin Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin powder for inhalation (TIP)
Study: 22884560
Drug: Ranolazine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (500 to 1,000 mg orally twice daily)
Study: 21047592
Drug: Active monitoring,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active monitoring, radiotherapy, and radical prostatectomy treatments
Study: 11980329
Drug: Vancomycin 2
Normalized name: vancomycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 2 g per day (Group 1, n = 10)
Study: 11980329
Drug: Vancomycin with
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin with cefpirome 2 g x 2 (Group 2, n = 10)
Study: 10077374
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg) once daily
Study: 10077374
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg) once daily
Study: 7562574
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous cocaine doses (0, 8, 16, 32 or 48 mg/70 kg) administered 1 hr after daily methadone
Study: 7562574
Drug: Repeated intravenous
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intravenous cocaine doses (0, 8 or 32 mg/70 kg) administered 4 times per session at 14‐min intervals
Study: 7562574
Drug: Higher methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher methadone doses (> 60 mg)
Study: 7562574
Drug: Cocaine administration
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine administration in methadone-maintained individuals
Study: 7396155
Drug: Alcohol 0.5
Normalized name: isopropyl alcohol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.5 mg/kg
Study: 29078780
Drug: Apple polyphenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple polyphenol extract (100 mg epicatechin daily for 4 weeks)
Study: 25749867
Drug: NNC0109-0012 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0109-0012 administered subcutaneously at various dose levels (0.01-3 mg/kg) as single dose, once weekly, or multiple doses every second week for up to 12 doses.
Study: 24732962
Drug: Internet-based writing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based writing therapy with therapeutic interaction, 14 sessions
Study: 27247843
Drug: Medication (placebo)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (placebo)
Study: 28103159
Drug: Medication (methylphenidate)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (methylphenidate) without sports training
Study: 25891307
Drug: Individual reminiscence
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual reminiscence therapy (1 hour/week for 4 weeks)
Study: 24063204
Drug: Tongguan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongguan Capsule (TC)
Study: 14764772
Drug: Cabergoline treatment
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline treatment for 6 months
Study: 8620275
Drug: Meropenem (MP)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MP) 1,000 mg every eight hours
Study: 8620275
Drug: Tobramycin 5
Normalized name: tobramycin 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 5 mg/kg/day and Clindamycin 900 mg every eight hours (T/C)
Study: 18200773
Drug: Controlled-release nifedipine
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release nifedipine added once daily to ARB
Study: 18200773
Drug: Increasing ARB
Normalized name: revakinagene taroretcel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing ARB dosage
Study: 11190754
Drug: Budesonide 280
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 280 micrograms once daily
Study: 11190754
Drug: Budesonide 140
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 140 micrograms once daily
Study: 9355432
Drug: Lidocaine 2.5%
Normalized name: LIDOCAINE 2.5% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2.5% ointment
Study: 3534900
Drug: Clonidine (single-dose)
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine (single-dose)
Study: 29856286
Drug: Conventional psychiatric
Normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional psychiatric treatment (control group)
Study: 27327616
Drug: Two injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two injections of MVA (MM group)
Study: 27327616
Drug: One injection
Normalized name: naloxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection of Placebo and one injection of MVA (PM group)
Study: 12714433
Drug: Isoflavones (biochanin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (biochanin or formononetin, 80 mg/d)
Study: 1713709
Drug: MK-329 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-329 (10 mg orally)
Study: 6351619
Drug: Oral tinidazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tinidazole, 500 mg twice daily for 5 days
Study: 6351619
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo with vaginal cream (with or without sulfonamides)
Study: 6351619
Drug: Vaginal sulfonamide
Normalized name: 2-acetylamino-1,3,4-thiadiazole-5-sulfonamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal sulfonamide cream with oral placebo
Study: 29025878
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor antagonist exendin 9-39 (Ex9-39)
Study: 22622049
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of MCV4
Study: 22622049
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of MCV4
Study: 22622049
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of MCV4 in subjects with CD4% <15
Study: 19417618
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral rifampin once daily for 7 days
Study: 15382436
Drug: Endovesical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovesical treatment with Bacillus Calmette Guerin (BCG) for 12 months
Study: 15382436
Drug: Endovesical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovesical treatment with Bacillus Calmette Guerin (BCG) for 6 months
Study: 15382436
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no BCG treatment)
Study: 3293891
Drug: Non-meat protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-meat protein supplement
Study: 3293891
Drug: Meat protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat protein supplement
Study: 31128285
Drug: Antibiotic exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic exposure
Study: 30392115
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg/day; 3 weeks on/1 week off) plus fulvestrant (500 mg)
Study: 8626983
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite inhalation
Study: 19463380
Drug: Aspirin resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin resistant patients (ARU >= 550)
Study: 19463380
Drug: Aspirin sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin sensitive patients
Study: 16556246
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment for headaches
Study: 30241150
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m2
Study: 30241150
Drug: Bleomycin 15
Normalized name: bleomycin 15 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin 15 IU/m2 and Vincristine 1.4 mg/m2
Study: 26818604
Drug: Hummus alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hummus alone (2.7 g, 10.8 g, 25 g avCHO)
Study: 26818604
Drug: Hummus plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hummus plus white bread (2.7 g, 5.4 g, 10.8 g avCHO)
Study: 26818604
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread (25 g avCHO)
Study: 26818604
Drug: White bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White bread (50 g avCHO)
Study: 24745810
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (maintaining hemoglobin 10.0 g/dL > hemoglobin ≧ 8.0 g/dL)
Study: 24745810
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (maintaining hemoglobin ≧ 10.0 g/dL)
Study: 16842396
Drug: Solifenacin and
Normalized name: tamsulosin and solifenacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin and warfarin or digoxin
Study: 12491520
Drug: Peptides/IFA with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptides/IFA with GM-CSF (250 microm subcutaneously daily for 5 days)
Study: 10850937
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) at doses of 0.075 IU/kg, 0.150 IU/kg, and 0.300 IU/kg for 5 postoperative days
Study: 1818790
Drug: Captopril (41
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (41 +/- 3 mg in three divided doses)
Study: 1818790
Drug: Enalapril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (8 +/- 1 mg once daily)
Study: 31472076
Drug: Drought treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drought treatment
Study: 11196519
Drug: Home based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home based physical therapy (PT) intervention (education, exercise, and pain relief modalities) delivered by physiotherapists with advanced rheumatology training for 6 weeks.
Study: 7989934
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy regimens and CNS prophylaxis regimens (intrathecal methotrexate alone or intrathecal methotrexate plus 18 Gy cranial irradiation)
Study: 29193019
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg/day orally on days 1-21; 28-day cycles)
Study: 29193019
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice (IC) therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine)
Study: 24740312
Drug: Sugammadex 1
Normalized name: sugammadex 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 1 mg·kg(‐1)
Study: 19707086
Drug: Automated telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated telephone intervention (daily messages regarding diabetes)
Study: 15300580
Drug: Nadolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (mean dose 62 +/- 25 mg/day, adjusted to decrease resting heart rate by 25%)
Study: 11123382
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MDMA and ethanol
Study: 8095150
Drug: epanolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol (200 mg once daily)
Study: 8095150
Drug: diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem (60 mg three times daily)
Study: 3688375
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BPD) at concentrations of 0.1 mg/ml, 0.05 mg/ml, 0.005 mg/ml, and 0.0005 mg/ml
Study: 3688375
Drug: Flunisolide at
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide at concentrations of 0.25 mg/ml, 0.05 mg/ml, 0.025 mg/ml, and 0.00025 mg/ml
Study: 3688375
Drug: Propylene glycol
Normalized name: Propylene Glycol
DrugBank: Propylene glycol (DB01839)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propylene glycol at concentrations of 20 mg/ml and 200 mg/ml
Study: 23887076
Drug: multimodal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: multimodal analgesic regimen (celecoxib, pregabalin, extended release oxycodone)
Study: 23887076
Drug: intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous morphine
Study: 20033052
Drug: Intermediate- or
Normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate- or high-dose methotrexate therapy
Study: 20033052
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg/m(2)
Study: 16736065
Drug: Standard formula
Normalized name: Standard formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formula and simethicone (6 mg/kg twice a day)
Study: 12745852
Drug: Ketoconazole cream
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole cream
Study: 10965161
Drug: tolcapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone (200 mg t.i.d.)
Study: 8988072
Drug: Atorvastatin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 0.5 to 80 mg/day
Study: 7698138
Drug: Diuretic (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (hydrochlorothiazide + triamterene)
Study: 29482588
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg twice daily for 18 months
Study: 29354993
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medication (oral acyclovir, vitamin B1, mecobalamin tablets, and interferon injection)
Study: 24406537
Drug: Cardiac pacing
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac pacing therapy
Study: 24406537
Drug: No cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cardiac pacing therapy (Control)
Study: 9507787
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg plus diltiazem ER 120 mg or 180 mg
Study: 3275523
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (2 mg for 3 weeks, followed by dose reductions and placebo)
Study: 3275523
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (30 mg for 3 weeks, followed by dose reductions and placebo)
Study: 30422257
Drug: Antipsychotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medications (5 atypical and 2 typical) for 6 weeks
Study: 14557155
Drug: Epinephrine vs
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine vs Albuterol sulfate (salbutamol)
Study: 6363660
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg/kg/day in three doses for 10 days)
Study: 6363660
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg/day in three doses for 10 days)
Study: 6363660
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Amoxicillin and Cefaclor)
Study: 31449469
Drug: Proton beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton beam radiation therapy
Study: 22391537
Drug: CMX001 (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMX001 (0.25 to 2.0 mg/kg single doses; 0.1 to 1.0 mg/kg multiple doses, 3 doses every 6 days)
Study: 20528000
Drug: Fixed maintenance-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed maintenance-dose budesonide/formoterol
Study: 20528000
Drug: Adjustable maintenance-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable maintenance-dose budesonide/formoterol
Study: 20528000
Drug: Fixed maintenance-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed maintenance-dose salmeterol/fluticasone propionate
Study: 17585004
Drug: 5-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day antibiotic therapy duration
Study: 17585004
Drug: 10-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day antibiotic therapy duration
Study: 17585004
Drug: Dosing frequency
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing frequency (once daily vs. twice daily)
Study: 12140400
Drug: Platelet aggregation
Normalized name: Platelet aggregation inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet aggregation inhibitors
Study: 12140400
Drug: Cholesterol‐lowering medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol‐lowering medication
Study: 12140400
Drug: Antidiabetic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiabetic agents
Study: 10400003
Drug: Quinapril (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (40 mg daily for two weeks)
Study: 10400003
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg daily for two weeks)
Study: 7675968
Drug: Scopolamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.5 mg SC)
Study: 7675968
Drug: Lorazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (2.5 mg PO)
Study: 2188379
Drug: Bezafibrate 200
Normalized name: bezafibrate 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 200 mg three times daily
Study: 30903423
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of group dynamic assessment and vocabulary exercises
Study: 21954478
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto extract (320 mg/d)
Study: 19703372
Drug: Intranasal sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal sumatriptan 10 mg